DNA Stock Recent News

Ginkgo Bioworks Holdings (NYSE: DNA ), which develops platforms for cell programming, has multiple, positive potential catalysts and a rather low valuation. Moreover, the shares should benefit from investors' recent interest in buying small-cap stocks that have lost a great deal of their value.

Biotechnology specialist Ginkgo Bioworks (NYSE: DNA ) is seeing shares skyrocket today following an announcement of a potentially lucrative collaboration. Specifically, Ginkgo will partner with Syngenta, which is billed as a “leader in agricultural innovation.

BASEL, Switzerland & BOSTON--(BUSINESS WIRE)--Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new cooperation aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology. Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can mee.

Syngenta will leverage Ginkgo's Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution BASEL, Switzerland and BOSTON , July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology.

Ginkgo Bioworks is scaling down its workforce and operating footprint. It's also aiming to restrict the scope of the services it offers.

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.32, representing a -1.51% change from its previous close.

High-risk penny stocks are known for their volatility. They often feature low trading volumes, minimal prices and unstable financial and fundamental standings.

There's definitely a science to picking beaten-down gems in the stock market. If you get it wrong, you could lose a lot of money.

In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.

Ginkgo Bioworks (NYSE: DNA ) layoffs continue today with the cell programming company announcing additional job cuts. The latest update to the Ginkgo Bioworks layoffs reveals that the company is planning to cut at least 35% of its workers.